active
ACTIVE SINCE: 1998

International Trachoma Initiative (ITI)

Providing trachoma endemic countries with donated antibiotics that are a critical component of the global strategy to eliminate this neglected tropical disease (NTD).
SGDS CONTRIBUTING TO:
SHOW SUB-TARGETS + HIDE SUB-TARGETS -
MEMBER COMPANIES:
Government 4
Private Foundation or Development Organization 1
Intergovernmental Organizations and Multilaterals 1
Academia or research institute 3
Bilateral development organizations 2
Global NGOs 2
Objectives
  • To provide trachoma endemic countries with donated antibiotics that are a critical component of the global strategy to eliminate this neglected tropical disease (NTD).

Approximately 158 million people are at risk of developing trachoma and this recommitment ensures that through 2025, Pfizer, through the International Trachoma Initiative (ITI), will continue to provide trachoma endemic countries with donated antibiotics that are a critical component of the global strategy to eliminate this neglected tropical disease (NTD).

In 2018, Pfizer announced the extension of the Zithromax® antibiotic donation program through 2025 to help eliminate trachoma.

Quote
"Continued antibiotic donations are essential to maintaining this progress, and while much work remains, I am more confident than ever that we can eliminate this ancient disease within the next decade.”
Dr. Paul Emerson
Director, ITI
Results and milestones

In 2018 Pfizer celebrated 20 years of commitment to eliminating blinding trachoma and another exciting milestone – more than 800M doses of Zithromax have been donated in more than 40 countries since the program began. Just over 100 million of those doses were shipped in 2018.

Our experience has shown us that collaboration is essential to solving complex global public health challenges. An example of this approach is our work with the International Trachoma Initiative (ITI), part of a global network of more than 100 diverse partners working together to eliminate trachoma, the world’s leading infectious cause of blindness. Trachoma primarily affects remote communities with severely limited access to health care, clean water or sanitation, and nearly 157.7 million people are living in trachoma-endemic areas in 43 countries.

Geographic Reach
  • Global Commitment
Disease Area
Target Population
  • Marginalized/indigenous people
  • People with low incomes
  • Rural populations
Partner organizations
Government

Ministry of Health Uganda

Ethiopian Ministry of Health

Ministry of Health Malawi

Ministry of Health Nigeria

Private Foundation or Development Organization

Fred Hollows Foundation

Intergovernmental Organizations and Multilaterals

World Health Organization (WHO)

Academia or research institute

Johns Hopkins University

London School of Hygiene & Tropical Medicine (LSHTM)

University of California, Berkeley

Bilateral development organizations

UK Department for International Development (DFID)

US Agency for International Development (USAID)

Global NGOs

Carter Center

Sightsavers International